Type 2 diabetes is linked to impaired pulmonary function

  • Díez-Manglano J & al.
  • ERJ Open Res
  • 1 Jan 2021

  • curated by Miriam Tucker
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Type 2 diabetes (T2D) is associated with pulmonary function impairment, independent of sex, smoking status, or worldwide location.

Why this matters

  • Pulmonary function test (PFT) impairment has not been well-studied in people with T2D.

Study design

  • A meta-analysis including 66 studies of 11,134 individuals with T2D and 48,377 control participants without T2D.
  • Funding: None.

Key results

  • Pooled mean differences were as follows:
    • Predicted percentage of FEV1 (41 studies): −7.15 (P<.0001>
    • Predicted percentage of FVC (35 studies): −9.21 (P<.0001>
    • FEV1/FVC ratio (45 studies): −0.27 (P<.69>
    • Forced expiratory flow at 25%-75% of total lung capacity (13 studies): −9.89 (P<.0001>
    • Predicted percentage of peak expiratory flow (15 studies): −9.79 (P<.0001>
  • No differences by sex in 15 studies (P>.25 for all measures).
  • For tobacco use (14 studies included smokers+nonsmokers; 43 nonsmokers only; 9 no smoking data): reductions in lung function measures were greater in studies of nonsmokers than in those that included both (P<.001>
  • Abnormal PFT results observed in those with T2D in all continents.

Limitations

  • Discrepancies in study selection and quality assessment resolved by consensus.
  • Heterogeneity between studies.
  • Only half of the studies included ≥50 with T2D.
  • Most studies did not report results by sex.